Treatment-resistant disease.

A pill may provide hope to relapsed lymphoma and leukemia patients A pill that suppresses an integral regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology . Patients with blood cancer are typically administered a combination of chemotherapy and immunotherapy, the latter using the body's have immune system to help fight disease, while a first type of treatment.

Upon examining the surgically removed spinal cord tumor, the scientists decided that the tumor arose from the stem cells of at least two donors. The tumor was made up of both female and male cells and the tumor cells acquired two regular copies of the gene that triggers ataxia telangiectasia when mutated. As the 1st documented case of human being neural fetal stem cell injections resulting in tumor growth, this whole story provides captured media attention worldwide — spurring discussions on what the safety of stem cell therapies ought to be evaluated. As for the authors of this article, they recommended more study on stem cell therapy basic safety, but did not recommend halting stem cell research.